Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $137000.0.

  • Pharma's Total Non-Current Liabilities fell 2789.47% to $137000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $137000.0, marking a year-over-year decrease of 2789.47%. This contributed to the annual value of $160000.0 for FY2025, which is 3361.0% down from last year.
  • According to the latest figures from Q3 2025, Pharma's Total Non-Current Liabilities is $137000.0, which was down 2789.47% from $140000.0 recorded in Q2 2025.
  • Pharma's 5-year Total Non-Current Liabilities high stood at $696000.0 for Q1 2021, and its period low was $137000.0 during Q3 2025.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $340000.0 (2023), whereas its average is $353842.1.
  • Examining YoY changes over the last 5 years, Pharma's Total Non-Current Liabilities showed a top increase of 3892.22% in 2021 and a maximum decrease of 4673.23% in 2021.
  • Quarter analysis of 5 years shows Pharma's Total Non-Current Liabilities stood at $534000.0 in 2021, then dropped by 25.66% to $397000.0 in 2022, then tumbled by 31.99% to $270000.0 in 2023, then plummeted by 40.0% to $162000.0 in 2024, then decreased by 15.43% to $137000.0 in 2025.
  • Its last three reported values are $137000.0 in Q3 2025, $140000.0 for Q2 2025, and $160000.0 during Q1 2025.